Ariad Investor Says Drug Side Effects Led To Stock Drop
An investor hit Ariad Pharmaceuticals Inc. with a putative class action in Massachusetts federal court on Thursday, alleging the oncology company made false statements about its leukemia drug Iclusig then disclosed...To view the full article, register now.
Already a subscriber? Click here to view full article